Berry Global Group, Inc. (NYSE: BERY) today announced that it is investing in a state-of-the-art Reicofil R5 asset to provide incremental capacity to serve the fast growing Asia healthcare markets. The investment is targeted to meet forecasted market and customer growth and will be focused on high performance applications in the desired healthcare markets. The nonwovens investment supports Berry’s strategy to further its leadership position in healthcare.
The new asset will be installed at Berry’s Nanhai, China, facility, which is strategically positioned to serve customers in the rapidly growing Southeast Asia region. Current projections are for startup in the September quarter of 2022.
“We are committed to further partnering with our customers to pursue growth opportunities around the world. The added capacity achieved through this asset is a next step in advancing our market leading position in healthcare material solutions,” said Curt Begle, President of Berry’s Health, Hygiene, and Specialties Division. “This investment comes on the heels of the successful commercialization of the first of its kind R5 asset in Berry’s Nanhai, China, facility, serving the high-loft soft material needs of the premium hygiene markets throughout the Asia region.”
Berry will be the first company in the world to secure two state-of-the-art R5 assets. Once installed, the asset will be critical in the manufacturing of healthcare nonwoven materials, primarily surgical drapes and gowns.
https://ir.berryglobal.com/news-releases/news-release-details/berry-global-announces-investment-healthcare-asset